In HSCs with JAK2 mutations, there is an overproduction of activated leukocytes and platelets, leading to the release of excessive reactive oxygen species, pro-inflammatory cytokines, and thromboxane, all of which collectively increase the risk of arterial and venous thrombosis [26]. Here, JAK2 is linked to Venous thrombosis.